ANXA9 facilitates S100A4 and promotes breast cancer progression through modulating STAT3 pathway

Xiqian Zhou,Junyong Zhao,Tao Yan,Danrong Ye,Yuying Wang,Bai’an Zhou,Diya Liu,Xuehui Wang,Wenfang Zheng,Bowen Zheng,Fengyuan Qian,Yating Li,Dengfeng Li,Lin Fang

DOI: https://doi.org/10.1038/s41419-024-06643-4

2024-04-14

Cell Death and Disease

Abstract:Breast cancer has the highest global incidence and mortality rates among all cancer types. Abnormal expression of the Annexin family has been observed in different malignant tumors, including upregulated ANXA9 in breast cancer. We found highly expressed ANXA9 in metastatic breast cancer tissues, which is correlated with breast cancer progression. In vitro, the functional experiments indicated ANXA9 influenced breast cancer proliferation, motility, invasion, and apoptosis; in vivo, downregulation of ANXA9 suppressed breast cancer xenograft tumor growth and lung metastasis. Mechanically, on one side, we found that ANXA9 could mediate S100A4 and therefore regulate AKT/mTOR/STAT3 pathway to participate p53/Bcl-2 apoptosis; on the other side, we found ANXA9 transferred S100A4 from cells into the tumor microenvironment and mediated the excretion of cytokines IL-6, IL-8, CCL2, and CCL5 to participate angiogenesis via self- phosphorylation at site Ser2 and site Thr69. Our findings demonstrate significant involvement of ANXA9 in promoting breast cancer progression, thereby suggesting that therapeutic intervention via targeting ANXA9 may be effective in treating metastatic breast cancer.

cell biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role of ANXA9 (Annexin A9) in the progression of breast cancer (BC) and its potential molecular mechanisms. Specifically, the researchers focus on the following aspects:

1. **Expression of ANXA9 in breast cancer**:
- The study found that ANXA9 is highly expressed in metastatic breast cancer tissues, and this high - expression is related to the progression of breast cancer.

2. **Effect of ANXA9 on the functions of breast cancer cells**:
- In vitro experiments show that ANXA9 affects the proliferation, migration, invasion and apoptosis of breast cancer cells.
- In vivo experiments indicate that down - regulating ANXA9 can inhibit the growth and lung metastasis of breast cancer xenografts.

3. **Interaction between ANXA9 and S100A4**:
- The study found that ANXA9 can participate in the AKT/mTOR/STAT3 signaling pathway by regulating S100A4, and then regulate the p53/Bcl - 2 apoptosis pathway.
- ANXA9 can also transfer S100A4 from the intracellular to the tumor microenvironment, and secrete cytokines IL - 6, IL - 8, CCL2 and CCL5 through the autophosphorylation sites Ser2 and Thr69, participating in angiogenesis.

4. **Regulation of apoptosis and signaling pathways by ANXA9**:
- ANXA9 regulates the apoptosis of breast cancer cells through the p53 pathway.
- Down - regulating ANXA9 increases the half - life of p53 protein and prevents its degradation through the ubiquitin - proteasome pathway, resulting in the accumulation of p53 in the cytoplasm.

5. **Role of ANXA9 in breast cancer metastasis**:
- ANXA9 helps cancer metastasis through angiogenesis by regulating the expression and secretion of S100A4 and recruiting multiple cytokines.

In summary, this study aims to reveal the key role of ANXA9 in promoting the progression of breast cancer and provide a theoretical basis for treatment interventions targeting ANXA9. The research results show that ANXA9 is a potential treatment target for breast cancer, especially of great significance in the treatment of metastatic breast cancer.